Approve

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.

• The FDA has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, specifically targeting adults aged 50 and older. • The regulatory strategy includes full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, pending a postmarketing study using a high-dose comparator. • This approval follows a unanimous recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee in June 2026.

• The FDA has approved the first mRNA-based flu vaccine, developed by Moderna, specifically for adults aged 50 and older. • Former FDA vaccine regulator Jesse Goodman noted the shot's documented superiority in effectiveness over standard doses for the 50-64 age group, particularly those with underlying health conditions. • The new vaccine serves as a potent alternative for seniors 65 and over and will be covered by Medicare, according to KFF health policy expert Jennifer Kates.

Culture secretary Lisa Nandy says she will not intervene in £85bn deal after securing guarantees on Channel 5The UK culture secretary, Lisa Nandy, has said she will not intervene in Paramount’s proposed acquisition of Warner Bros Discovery, removing one of the remaining obstacles to the blockbuster deal.However, Paramount has made significant concessions to secure the UK government’s backing for the $110bn (£85bn) takeover, which will create a global media powerhouse and effectively bolster the influence of Paramount’s CEO, David Ellison. Continue reading...

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics. • The shift to mRNA for flu shots is critical because the technology allows for faster production and potentially better matching to evolving seasonal virus strains.

• Spain's Interior Minister Fernando Grande-Marlaska provided updated estimates on migrants who entered Ceuta last week as the Spanish government approves millions in funding to manage the crisis. • During emergency talks on Tuesday, EU ministers discussed the situation, with Denmark and Italy specifically pushing for more stringent migration measures. • Danish Immigration Minister Morten Bodskov called for increased EU funding for border security to prevent a recurrence of the 2015-16 migration crisis, which saw over a million refugees enter Europe.

• India approved only one Foreign Direct Investment (FDI) proposal from China worth Rs 1 crore during the last financial year. • In contrast, the government cleared 13 FDI applications from Hong Kong totaling Rs 610.42 crore. • These figures highlight the strict regulatory environment for investments from countries sharing a land border with India, which require prior government approval.